Next Arc Research

Not logged in? You're viewing the Free tier. Join for free or log in to access your membership content.
Disclaimer: This content is for informational and educational purposes only and should not be construed as financial or investment advice. Always do your own research and consult a licensed financial advisor before making investment decisions.
Disclosure: The author holds a long position in CRSP.
← Back to Free Index

CRSP

Analysis as of: 2026-03-14
CRISPR Therapeutics AG
Gene-editing biotech developing ex vivo, in vivo and cell therapies, with shared economics on CASGEVY and a broader internal pipeline.
biotech healthcare
On Yahoo Finance ...
Jump to: Summary • Analysis • Opportunity • Risk • Trends • LE Structure • Third Party Analyst Consensus

Summary

A Real Product, Still a Platform Test
The upside case is straightforward: one approved gene-editing therapy becomes a commercial base and the next clinical wave proves the company can repeat the process across new disease areas. The reason the stock is not already priced there is equally straightforward: those next proofs are still ahead, and the first launch is partly controlled by a partner.

Analysis

Thesis
CRISPR Therapeutics has moved beyond pure platform promise: if CASGEVY keeps scaling and 2026-2027 validates at least one owned in vivo program plus one immune franchise, the stock can rerate from a cash-backed single-asset story to a real multi-franchise gene-editing company by 2031.
Last Economy Alignment
AI should lower discovery and process iteration costs, while value capture stays in IP, delivery know-how and regulated manufacturing rather than commoditized software. The cap is that clinical proof, treatment logistics and Vertex-controlled commercialization still gate scale.
Upgrade to Allocator to also access: Thesis Critique

Opportunity Outlook

Average Implied 5-Year Multiple
4.2x (from 5 most recent analyses)
Reasoning
I use a revenue path because 2031 value should still be driven by franchise breadth and de-risking, not mature cash flow. A realistic upside case is steady CASGEVY expansion plus clear validation of one owned cardiometabolic or immune program and one partnered program. That would justify a real platform premium, but not the valuation of a fully de-risked commercial biotech.
Upgrade to Allocator to also access: Simplified Opportunity Explanation

Risk Assessment

Overall Risk Summary
The main risk is not AI-style software commoditization; it is conversion risk. CRSP must prove that one approved gene-editing therapy can become durable commercial throughput and that follow-on programs can reproduce human efficacy and safety across new modalities. If 2026-2027 data slip or disappoint, the stock can fall back toward a cash-plus-optionality framework even with a strong balance sheet.
Upgrade to Allocator to also access: Tech Maturity Risk Score, Adoption Timing Risk Score, Moat Strength Risk Score, Capital Needs Risk Score, Regulatory Risk Score, Execution Risk Score, Concentration Risk Score, Unit Economics Risk Score, Valuation Risk Score, Macro Sensitivity Risk Score

Last Economy Structure

AI Industrial Score
0.36
They already helped get one gene-editing therapy approved and own useful control points in delivery, manufacturing and follow-on program design. AI helps them improve programs faster, but regulators, treatment logistics and a partner-controlled launch still limit how much value they can keep.
Upgrade to Reader to also access: Score Decomposition, Confidence Level
Upgrade to Allocator to also access: Obsolescence Vectors, Pricing Fragility
Upgrade to Reader to also access: Constraint Benefit Score, Obsolescence Risk Score

Third Party Analyst Consensus

12-Month Price Target
$70.00
Upgrade to Reader to also access: Bull Case, Base Case, Bear Case